Corporate Governance

Board of Directors

Michael is a co-founder and Chairman of the Board of Tarsus. He is also co-founder, former-CEO and serves on the board of Presidio Medical. He formerly served as Chairman of Oyster Point Pharma, Inc. (NASDAQ: OYST). He was also previously Vice President, Neurostimulation for Allergan (an AbbVie company) after serving as CEO of Oculeve, Inc., which was acquired by Allergan. He received a B.E. degree in biomedical engineering from Vanderbilt University and M.S. and Ph.D. degrees in biomedical engineering from Case Western Reserve University. He is a graduate of Stanford University’s Biodesign Fellowship and Vision Research Fellowship. He has numerous patents and peer-reviewed publications.

Chairman of the Board
Member of the Compensation Committee
Chair of the Nominating & Corporate Governance Committee
Member of the Science & Technology

Bhaskar is Operating Partner at Frazier Healthcare Partners where he joined in 2011 and brings to the Life Sciences team significant operational experience in drug research, development, and commercialization in the United States, Europe, and emerging markets. He leads investments in later-stage companies and in international opportunities and is a co-founder of Arcutis (NASDAQ: ARQT), where he currently serves on the Board. Bhaskar also serves on the Board of Teligent (NASDAQ: TLGT) and is an advisor to the Johns Hopkins Berman Institute of Bioethics. Bhaskar also served on the board of directors of Silvergate Pharmaceuticals (acquired by CutisPharma), Corium International (acquired by Gurnet Point Capital) and Thesan Pharmaceuticals.

Prior to joining Frazier, Bhaskar was President of Valeant Pharmaceuticals, where he led Valeant’s international operations and business development activities. He joined Valeant through its acquisition of Dow Pharmaceutical Sciences, where he had been President and CEO. Before Dow, Bhaskar worked at Mylan Pharmaceuticals in several capacities including EVP of Scientific Affairs at Mylan subsidiary Bertek Pharmaceuticals, and as General Manager of the Dermatology Division. Earlier, he worked at Penederm, a skin-products and drug-delivery company, as VP of R&D.

Bhaskar holds a Ph.D. in Pharmaceutics, a M.S. in Industrial Pharmacy and a B.S. in Pharmacy.

Member of the Audit Committee

Rose has more than 30 years of extensive experience in the pharmaceutical industry, including executive leadership, board service, innovation, business development, and global commercialization expertise. She brings significant executive leadership and operating expertise to the Tarsus Board, having previously served as President and Chief Executive Officer of both MELA Sciences, Inc. (now Strata Skin Sciences) and Epocrates, Inc., as well as Partner and Head of Commercialization at Appletree Partners. Prior to that, Ms. Crane held several senior executive positions at Johnson & Johnson, including Group Chairman, OTC & Nutritional Group, leading the largest worldwide OTC company. Earlier in her career, she spent 20 years at Bristol Myers Squibb, completing her tenure as President, U.S. Primary Care.

Ms. Crane has served on the boards of several pharmaceutical and life sciences companies, including Edge Therapeutics, Inc., Unilife Corporation, Cipher Pharmaceuticals Inc., Targanta Therapeutics Corp., and Zealand Pharma A/S. She currently serves on the boards of Teva Pharmaceuticals Industries Ltd. and Catalent, Inc., as well as serving as a director of the Hackensack Meridian Health Center for Discovery and Innovation. Ms. Crane received a B.A. in communications and English from the State University of New York at Oswego and an MBA from Kent State University.

Chair of the Audit Committee
Chair of the Science & Technology
Andrew is a Principal at Vivo Capital based in Palo Alto where he helps lead investments in private pharmaceutical and medical device companies across all life-cycle stages.  Prior to Vivo, Dr. Goldberg worked at McKinsey & Company in their Silicon Valley office, where he served global pharmaceutical, medical device, and biotechnology companies across a range of strategy, M&A, sales, marketing, and product development topics. Dr. Goldberg currently serves or has served on the board of several life sciences companies including Swift Health Systems Inc (Chairman), Arcutis Biotherapeutics (ARQT) (observer), Instil Bio (observer), Harmony Biosciences (observer), Impel Neuropharma (observer).  Other representative investments include River Vision (acquired by Horizon) and Tricida (TCDA).
 
Dr. Goldberg is a U.S. board-certified physician in both Critical Care Medicine and Emergency Medicine. He served as an Instructor in Medicine at the Mayo Clinic College of Medicine in Rochester, MN, where he completed a fellowship in Critical Care Medicine and served as an Attending Physician in the Department of Emergency Medicine. Prior to this, he completed Emergency Medicine residency training at Los Angeles County + University of Southern California Medical Center (LAC+USC).

Dr. Goldberg received his M.D. from The George Washington University School of Medicine in Washington, DC, and has held academic and clinical appointments at the Stanford VA Palo Alto Medical Center, Oregon Health & Science University, the University of Arizona, and currently at the Washington Township Medical Foundation. 
Member of the Nominating & Corporate Governance Committee
Member of the Science & Technology

Bill is Founder and Managing Partner of Flying L Partners and a Founder and Managing Director of Versant Ventures. He specializes in early-stage investing in medical devices. Prior to co-founding Versant Ventures, Bill was a general partner at Brentwood Venture Capital and has over two decades of operations experience in the healthcare industry. Bill was previously Founder, Chairman, and CEO of Chiron Vision, which was sold to Bausch and Lomb in 1997. Prior to Chiron Vision, Bill founded and served as President of American Medical Optics (AMO), a division of American Hospital Supply Corporation, which was sold to Allergan in 1986. Later, he served on the Board of AMO’s successor company, Advanced Medical Optics (AMO) which was acquired by Abbott in 2009 and then by Johnson and Johnson in 2016.  Before entering the healthcare industry, he was an Assistant Professor in the Department of Surgery at the Indiana University School of Medicine. Bill currently serves on the board of several private companies as well as Glaukos (NYSE: GKOS) and Oyster Point Pharma, Inc. (NASDAQ: OYST). He previously served on the board of Edwards Lifesciences (NYSE: EW). He received his B.S., M.S., and Ph.D. from Purdue University.

Member of the Compensation Committee
Member of the Nominating & Corporate Governance Committee

Wendy has more than 30 years of experience in the biopharmaceutical industry, as a public company director and product commercialization leader, including 26 years at Merck & Co. Inc.

While at Merck, Wendy held positions of increasing seniority, most recently as Chief Marketing Officer. In that position, she led a global organization charged with all aspects of commercialization of pharmaceuticals in more than 20 therapeutic areas. She also served as General Manager, Cardiovascular/Metabolic U.S. Business Unit, and as Merck’s Senior Vice President of Human Resources. Earlier in her career, she was Vice President of the Women’s Health Care franchise for Johnson & Johnson’s Ortho-McNeil Pharmaceutical subsidiary.

Wendy has served on the boards of several public and private biotechnology and medical device companies, including St. Jude Medical, Medivation, Alder Biopharmaceuticals, Aratana Therapeutics, and Myokardia. She currently serves on the boards of Global Blood Therapeutics, Ideaya Biosciences, and Inovio Pharmaceuticals. Wendy received a B.S. in business administration from Portland State University and an M.B.A. from Temple University, Fox School of Business.

Chair of the Compensation Committee
Member of the Audit Committee